Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis
Authors' conclusion
False-positive and false-negative results remain a significant challenge in the use of commercial MSA assays.
Study context
- Population
- Studies evaluating commercial myositis-specific autoantibody assays against immunoprecipitation (IP); PubMed, Web of Science and Scopus through July 202423 studies
- Comparison
- Commercial myositis-specific autoantibody (MSA) assays vs IP assays as reference standard
- Outcome
- Pooled sensitivity and specificity of commercial MSA assays vs IP
Methodological detailshierarchical summary receiver operating characteristic (SROC) model, QUADAS-2 quality assessment
- Hierarchical SROC model
- QUADAS-2 quality assessment
Pooled result
As reported in the abstract
| Group | Pooled sensitivity, anti-MDA5 | Pooled sensitivity, anti-SAE | Pooled sensitivity, anti-PL-12 | Pooled sensitivity, anti-Jo-1 and anti-MDA5 | Pooled sensitivity, anti-Mi-2 | Pooled sensitivity, anti-NXP2 | Pooled sensitivity, anti-TIF1-γ |
|---|---|---|---|---|---|---|---|
| Enzyme immunoassay (EIA) | 95.7 % | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| Line blot assay (LBA) | — not stated in the abstract | 88.3 % | 87.2 % | 82.8 % | 67.4 % | 69.7 % | 63.8 % |
Pooled sensitivity, anti-MDA5
Enzyme immunoassay (EIA)95.7 %
Line blot assay (LBA)— not stated in the abstract
Pooled sensitivity, anti-SAE
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)88.3 %
Pooled sensitivity, anti-PL-12
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)87.2 %
Pooled sensitivity, anti-Jo-1 and anti-MDA5
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)82.8 %
Pooled sensitivity, anti-Mi-2
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)67.4 %
Pooled sensitivity, anti-NXP2
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)69.7 %
Pooled sensitivity, anti-TIF1-γ
Enzyme immunoassay (EIA)— not stated in the abstract
Line blot assay (LBA)63.8 %
— not stated in the abstract
- Pooled specificity across MSA assays
- 94.7 % to 99.3 %
Original publication
Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis. Semin Arthritis Rheum. Published 27 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →